Lack of Effects of the Genetic Polymorphisms of Interleukin-10 in Clinical Outcomes of COVID-19
Mariana Avendaño-Félix, Luis Antonio Ochoa‐Ramírez, Rosalío Ramos‐Payán, Maribel Aguilar‐Medina, Alfredo Ayala-Ham, Horacio Rendón‐Aguilar, Erik Lizárraga-Verdugo, Felipe de Jesús Peraza‐Garay, Juan José Ríos‐Tostado, Jesús Salvador Velarde‐Félix
Abstract
Interleukin-10 (IL-10) gene polymorphisms have been associated with severity and outcomes in patients with respiratory and nonrespiratory viral infections. The aim of this study was to assess whether rs1800871 and rs1800872 polymorphisms of IL-10 gene are associated with the clinical outcomes of COVID-19 in a Mexican population. Study subjects were 193 COVID-19 patients. The genotyping was carried out with real-time PCR and serum IL-10 levels were measured with enzyme-linked immunosorbent assay. Logistic regression analysis was used for analysis association with clinical outcomes. There was no evidence of an association between alleles, genotypes, or haplotypes frequencies between patient groups according to severity and outcomes. The rs1800871 and rs1800872 polymorphisms might not be genetic risk factors for severity and mortality for COVID-19 in Mexican mestizos patients from northwest Mexico.